ArticleJournal of clinical microbiology1999
Genotype dependence of hepatitis C virus load measurement in commercially available quantitative assays.
Article in Journal of clinical microbiology, 1999. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 76 citations in OpenAlex.
- Sensitivity of hepatitis C virus core antigen and antibody combination assays in a global panel of window period samples.Transfusion · 2015Article
- Correlation of viral loads with HCV genotypes: higher levels of virus were revealed among blood donors infected with 6a strains.PloS one · 2012Article
- A novel diagnostic target in the hepatitis C virus genome.PLoS medicine · 2009Article
- Performance characteristics of a quantitative hepatitis C virus RNA assay using COBAS AmpliPrep total nucleic acid isolation and COBAS taqman hepatitis C virus analyte-specific reagent.The Journal of molecular diagnostics : JMD · 2008Article
- Verification of an assay for quantification of hepatitis C virus RNA by use of an analyte-specific reagent and two different extraction methods.Journal of clinical microbiology · 2004Article
- Variable ratio of hepatitis C virus RNA to viral core antigen in patient sera.Journal of clinical microbiology · 2004Article
- Strengths and limitations of commercial tests for hepatitis C virus RNA quantification.Journal of clinical microbiology · 2004Article
- In vitro detection of dissimilar amounts of hepatitis C virus (HCV) subtype-specific RNA genomes in mixes prepared from sera of persons infected with a single HCV genotype.Journal of clinical microbiology · 2003Article
- Quantification of hepatitis C virus in human liver and serum samples by using LightCycler reverse transcriptase PCR.Journal of clinical microbiology · 2002Article
- External quality assessment program for qualitative and quantitative detection of hepatitis C virus RNA in diagnostic virology.Journal of clinical microbiology · 2002Article
- Performance of the New Bayer VERSANT HCV RNA 3.0 assay for quantitation of hepatitis C virus RNA in plasma and serum: conversion to international units and comparison with the Roche COBAS Amplicor HCV Monitor, Version 2.0, assay.Journal of clinical microbiology · 2002Article
- Comparative evaluation of the VERSANT HCV RNA 3.0, QUANTIPLEX HCV RNA 2.0, and COBAS AMPLICOR HCV MONITOR version 2.0 Assays for quantification of hepatitis C virus RNA in serum.Journal of clinical microbiology · 2002Article
- Correlation between mutations in the interferon sensitivity-determining region of NS5A protein and viral load of hepatitis C virus subtypes 1b, 1c, and 2a.Journal of clinical microbiology · 2001Article
- Molecular properties, biology, and clinical implications of TT virus, a recently identified widespread infectious agent of humans.Clinical microbiology reviews · 2001Review
- Changes in anti-viral effectiveness of interferon after dose reduction in chronic hepatitis C patients: a case control study.BMC gastroenterology · 2001Article
- Improved version 2.0 qualitative and quantitative AMPLICOR reverse transcription-PCR tests for hepatitis C virus RNA: calibration to international units, enhanced genotype reactivity, and performance characteristics.Journal of clinical microbiology · 2000Article
- Hepatitis C virus core mutations reduce the sensitivity of a fluorescence enzyme immunoassay.Journal of clinical microbiology · 2000Article
- Performance characteristics of a quantitative, homogeneous TaqMan RT-PCR test for HCV RNA.The Journal of molecular diagnostics : JMD · 2000Article
- Clinical evaluation of the automated COBAS AMPLICOR HCV MONITOR test version 2.0 for quantifying serum hepatitis C virus RNA and comparison to the quantiplex HCV version 2.0 test.Journal of clinical microbiology · 2000Article
- Assessment of viral loads in patients with chronic hepatitis C with AMPLICOR HCV MONITOR version 1.0, COBAS HCV MONITOR version 2.0, and QUANTIPLEX HCV RNA version 2.0 assays.Journal of clinical microbiology · 2000Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Standardization and genotype independence of methods used to quantify hepatitis C virus (HCV) RNA in clinical specimens are necessary for accurate assessment of the role of HCV quantitation as a prognostic marker for HCV infection and monitoring of the response to antiviral treatment. Commercially available methods used to measure HCV loads include PCR-based (Roche Monitor) and hybridization-based (Quantiplex bDNA-2) methods. Recently, a new version of the Roche Monitor assay (version 2.0) has become available; it has been modified to achieve more equal quantitation of different HCV genotypes. Consistent with previous reports, Roche Monitor version 1.0 substantially underestimated concentrations of RNA transcripts of types 2b, 3a, 4a, 5a, and 6a and virus loads in individuals infected with genotypes 2 to 6 relative to reference tests. However, version 2.0 achieved equivalent quantitation of each genotype over a narrow quantitative range (10(3) to 5 x 10(5) copies of RNA/ml) but significantly underestimated RNA concentrations above this range. The assay showed an equivalent inability to quantify high levels of HCV RNA in plasma samples, and this was responsible for the falsely narrow range of virus loads detected in HCV-infected individuals. In contrast, the Chiron bDNA-2 assay could only measure RNA concentrations in the upper quantitative range (2 x 10(5) to 5 x 10(7) copies of RNA/ml) but showed equivalent sensitivity for genotypes 1 to 5; however, concentrations of type 6a RNA transcripts and virus loads in clinical specimens from individuals infected with type 6a were underestimated by a factor of 2 to 4. Differences were observed between PCR- and hybridization-based assays in their relative quantitation of HCV RNA transcripts and HCV genomic RNA, which may cause problems with the use of transcripts for interassay calibration.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.